Tanner Pharma Group

Tanner Pharma Group

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Tanner Pharma Group is a privately held, revenue-generating services company that acts as a critical enabler in the global pharmaceutical supply chain. It partners with pharmaceutical companies, biotechs, and non-profits to navigate complex regulatory, logistical, and distribution challenges, ensuring patients can access medicines through expanded access programs, clinical trial supply, and international commercialization. With a mission-driven focus on health equity, the company leverages two decades of experience and a global network to manage drug shortages, post-trial supply, and market entry strategies for its partners. Its business model is entirely service-based, providing tailored solutions rather than developing its own therapeutic pipeline.

OncologyImmunologyRare Diseases

Technology Platform

Integrated global services platform for pharmaceutical access, comprising regulatory intelligence, a global distributor network in 120+ countries, and quality/compliance systems for international drug distribution and commercialization.

Opportunities

Growing demand from small-to-mid sized biotechs for global commercialization and expanded access services, as they lack internal infrastructure.
Increasing industry focus on health equity and patient access in emerging markets creates a larger addressable market for Tanner's core mission-driven services.

Risk Factors

Business is dependent on pharmaceutical industry outsourcing trends and R&D spending.
Operations are subject to complex, evolving international regulations; compliance failures could severely damage reputation.
Relies on a global network of third-party logistics partners, exposing it to supply chain disruptions.

Competitive Landscape

Tanner competes with other specialty pharmaceutical services and distribution companies, as well as the in-house logistics teams of large pharmaceutical firms. Its differentiation lies in its deep focus on complex access pathways (compassionate use, donations), its extensive global reach (120+ countries), and its strong mission-driven reputation in the non-profit and biotech sectors.